Based on the Omeros Corporation stock forecast from 1 analysts, the average analyst target price for Omeros Corporation is USD 9.00 over the next 12 months. Omeros Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Omeros Corporation is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Omeros Corporation’s stock price was USD 6.73. Omeros Corporation’s stock price has changed by -4.67% over the past week, -14.38% over the past month and +78.99% over the last year.
No recent analyst target price found for Omeros Corporation
No recent average analyst rating found for Omeros Corporation
Company Overview Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. Read Less
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive di...Read More
Frequently Asked Questions About Omeros Corporation (OMER) Stock
Based on ratings from 1 analysts Omeros Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on OMER's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for OMER is USD 9.00 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 9.
OMER stock's Price/Earning ratio is 1.33.
Our analysis grades OMER stock's Price / Earning ratio at D+. This means that OMER stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this OMER may be fairly valued for its sector
The last closing price of OMER's stock was USD 6.73.
The most recent market capitalization for OMER is USD 0.53B.
Based on targets from 1 analysts, the average taret price for OMER is projected at USD 9.00 over the next 12 months.
This means that OMER's stock price may go up by +33.73% over the next 12 months.
We can't find any ETFs which contains Omeros Corporation's stock.
As per our most recent records Omeros Corporation has 198 Employees.
Omeros Corporation's registered address is The Omeros Building, Seattle, WA, United States, 98119.
You can get more information about it from Omeros Corporation's website at https://www.omeros.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Omeros Corporation (OMER) Stock
Based on ratings from 1 analysts Omeros Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on OMER's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for OMER is USD 9.00 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 9.
OMER stock's Price/Earning ratio is 1.33.
Our analysis grades OMER stock's Price / Earning ratio at D+. This means that OMER stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this OMER may be fairly valued for its sector
The last closing price of OMER's stock was USD 6.73.
The most recent market capitalization for OMER is USD 0.53B.
Based on targets from 1 analysts, the average taret price for OMER is projected at USD 9.00 over the next 12 months.
This means that OMER's stock price may go up by +33.73% over the next 12 months.
We can't find any ETFs which contains Omeros Corporation's stock.
As per our most recent records Omeros Corporation has 198 Employees.
Omeros Corporation's registered address is The Omeros Building, Seattle, WA, United States, 98119.
You can get more information about it from Omeros Corporation's website at https://www.omeros.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for OMER !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
